Related Experiment Video
Updated: May 20, 2026
In Vivo Imaging of Leishmania infantum-infected Hamsters by Gingival Inoculation of Axenic Amastigotes Expressing Luciferase
Published on: April 4, 2025
[Ingavirin treatment of experimental parainfluenza pneumonia in Syrian hamsters]
Insights
Ingavirin effectively combats parainfluenza virus infection in hamsters by reducing viral load and lung damage. This promising antiviral agent shows potential for treating parainfluenza in clinical settings.
Area of Science:
- Virology
- Pharmacology
- Respiratory Medicine
Background:
- Parainfluenza viruses frequently cause upper respiratory tract infections, particularly in young children.
- Developing effective antiviral treatments for parainfluenza is a critical medical need.
Purpose of the Study:
- To evaluate the antiviral efficacy of Ingavirin against parainfluenza virus infection in a preclinical model.
- To investigate the in vivo and in vitro effects of Ingavirin on parainfluenza virus replication and pathogenesis.
Main Methods:
- A Syrian hamster model was used to simulate parainfluenza virus infection.
- The study assessed the impact of Ingavirin on viral infectious titer, pulmonary edema, and cellular infiltration in lung tissue.
- In vitro experiments were conducted to determine Ingavirin's effect on viral progeny infectivity.
Main Results:
- Ingavirin significantly restricted the parainfluenza virus infectious process in hamster lung tissue.
- Treatment with Ingavirin led to reduced infectious viral titers, decreased pulmonary edema, and less cellular infiltration.
- Ingavirin demonstrated an ability to diminish the infective activity of viral descendants in vitro, indicating an impact on viral replication.
Conclusions:
- Ingavirin exhibits significant antiviral activity against parainfluenza virus infection in vivo.
- The findings support the consideration of Ingavirin as a promising therapeutic agent for parainfluenza infections.
Abstract:
Parainfluenza viruses affect the upper respiratory tract in all age group patients, in children aged 6 months to 3 years in particular. The most urgent task is to design drugs to treat parainfluenza. This investigation studied the antiviral activity of Ingavirin (2-(imidazole-4-yl) ethanamide of pentandioic-1,5 acid) on a model of parainfluenza infection in Syrian hamsters. The drug was shown to restrict the infectious process in animal lung tissue. This restriction manifested itself as reductions in the infectious titer of parainfluenza virus in the lung tissue, in the degree of pulmonary edema and tissue cell infiltration, and in virus-specific lesion of bronchial epithelial cells. The in vitro experiments demonstrated the ability of Ingavirin to diminish the infective activity of viral descendants. The finding allows one to consider Ingavirin to be a promising antiviral agent that is active against parainfluenza infection in vivo.
